Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors

NCT01288430 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT01288430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01288430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors
Lead sponsor
Daiichi Sankyo
Phase
Phase 1
Overall status
Terminated
Start date
March 29, 2011
Completion date
February 13, 2014
Enrollment
60 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung carcinoma, solid tumors